By Laura Boyd Adjuvant nivolumab did not improve disease-free survival (DFS) compared with observation in patients with resected, EGFR/ALK-negative non–small-cell lung cancer (NSCLC) following surgery and adjuvant chemotherapy, according to results from the phase 3 EA5142 (ALCHEMIST) trial (NCT02595944) presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. At a median follow-up of 72.6 months, DFS outcomes were similar between treatment arms.